Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.13
- Piotroski Score 4.00
- Grade Buy
- Symbol (LEGN)
- Company Legend Biotech Corporation
- Price $39.77
- Changes Percentage (-0.92%)
- Change -$0.37
- Day Low $39.09
- Day High $40.73
- Year High $70.13
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $86.00
- High Stock Price Target $94.00
- Low Stock Price Target $60.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.58
- Trailing P/E Ratio -17.66
- Forward P/E Ratio -17.66
- P/E Growth -17.66
- Net Income $-518,254,000
Income Statement
Quarterly
Annual
Latest News of LEGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Highlights: CARVYKTI's Impressive Growth Amid ...
Legend Biotech's CEO expects sequential growth in Q4 without specific guidance. FDA regulations impact CAR-T production, but Legend Biotech leads in revenue and slots among commercial CAR-T brands....
By Yahoo! Finance | 1 week ago -
Legend Biotech Corporation (LEGN): Among Hedge Funds' Top Biotech Stock Picks
A list of the top biotech hedge funds and stocks was compiled, focusing on Legend Biotech Corporation. Biotech investments are risky due to clinical trials and high costs....
By Yahoo! Finance | 2 months ago -
Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History
Legend Biotech Corporation is a biopharmaceutical company specializing in cell therapies for oncology. Their lead product, LCAR-B38M, targets multiple myeloma, with a portfolio of CAR-T candidates for...
By Yahoo! Finance | 4 months ago
